RVTY Posts Q2 Earnings & Sales Beat, Raises '25 Sales View
GAAP EPS from continuing operations was 46 cents compared with 45 cents in the prior-year period.
Revenue Details
Based in Waltham, MA, this leading MedTech company reported revenues of $720.3 million, up 4.1% year over year and 3% organically. The top line beat the Zacks Consensus Estimate by 1.2%.
Segmental Details
Revvity reports under two operating segments — Life Sciences and Diagnostics.
Life Sciences
Revenues from this segment totaled $365.9 million, up 4% organically from the year-ago quarter's level.
Adjusted operating income amounted to $115 million, down 2.5% from the prior-year quarter's figure.
Diagnostics
This segment's revenues totaled $354.4 million, up 3% on a year-over-year basis. Organically, the top line increased 2% year over year.
Adjusted operating income amounted to $89 million, down 4.3% from the year-ago quarter's figure.
Margin Analysis
Selling, general and administrative expenses totaled $248.5 million, down 1.2% year over year. Research and development expenses amounted to $53.3 million, up 10.7% from the year-ago quarter's reported number.
Adjusted operating income declined 3.6% to $191.8 million from the year-ago quarter's level. Adjusted operating margin, as a percentage of revenues, was 26.6%, contracting 220 basis points.
Financial Update
The company exited the second quarter of 2025 with cash and cash equivalents of $991.8 million compared with $1.14 billion at the end of the prior quarter.
Net cash provided by operating activities totaled $134.3 million compared with $158.6 million in the year-ago quarter.
2025 Guidance
Revvity lowered its earnings outlook but raised its revenue guidance for 2025.
The company expects adjusted EPS to be in the range of $4.85-$4.95 (up from the earlier guidance of $4.90-$5.00). Revenues are now anticipated to be in the band of $2.84-$2.88 billion (previously $2.83-$2.87 billion). The Zacks Consensus Estimate for EPS and revenues is pegged at $4.82 and $2.85 billion, respectively.
Our Take
Revvity exited the second quarter of 2025 on a strong note, with both earnings and sales beating estimates and improving year over year. The company raised its revenue outlook due to a favorable currency movement as well as organic growth. The projection is now expected to grow 2-4% organically.
Shares of RVTY were down 5.9% during pre-market trading, likely due to a lower EPS outlook. The company's shares have lost 7.1% so far this year compared with the industry 's decline of 5.2%. The S&P 500 Index is up 8.2% in that period.
Image Source: Zacks Investment Research
However, solid execution across both Life Sciences and Diagnostics segments underscores the strength of its diversified portfolio. With momentum clearly building and management reaffirming full-year targets, Revvity is well-positioned to navigate ongoing challenges and capitalize on emerging opportunities, setting a confident tone for the remainder of 2025.
Last month, RVTY announced the launch of its new IDS i20 analytical random access platform from EUROIMMUN, enabling full automation of chemiluminescence immunoassays. In May, RVTY announced the launch of three Mimix reference standards for IVD use, designed for monitoring of next-generation sequencing (NGS) or droplet digital polymerase chain reacting (ddPCR) assays designed to detect somatic mutations in genomic DNA (gDNA) from human samples for IVD use. These should bring additional sales in the upcoming quarter, driving top-line growth further.
Moreover, the favorable ruling for RVTY in February in a litigation with its partner, Cloud Software Group, ensured uninterrupted access to the latter's Spotfire software. This will support Revvity and its customers' operational continuity and service quality.
RVTY's Zacks Rank & Stocks to Consider
RVTY carries a Zacks Rank #3 (Hold) at present.
Some better-ranked stocks from the broader medical space that are expected to report earnings soon are Align Technology ALGN, Cardinal Health, Inc. CAH and Cencora, Inc. COR.
The Zacks Consensus Estimate for Align Technology's second-quarter 2025 adjusted EPS is currently pegged at $2.57. The consensus estimate for revenues is pegged at $1.06 billion. ALGN currently carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
Align Technology has an estimated long-term growth rate of 11.2%. However, ALGN's earnings yield is 5.1% compared with the industry's 5.4%.
Cardinal Health currently has a Zacks Rank #2. The Zacks Consensus Estimate for fourth-quarter fiscal 2025 adjusted EPS is currently pegged at $2.03 and the same for revenues is pinned at $60.67 billion.
Cardinal Health has an estimated long-term growth rate of 10.9%. CAH's earnings yield of 5.7% compares favorably with the industry's 5.5%.
Cencora currently carries a Zacks Rank #2. The Zacks Consensus Estimate for third-quarter fiscal 2025 adjusted EPS is currently pegged at $3.78 and the same for revenues is pinned at $80.33 billion.
Cencora has an estimated long-term growth rate of 12.8%. COR's earnings yield of 5.4% compares favorably with the industry's 4.1%.
5 Stocks Set to Double
Each was handpicked by a Zacks expert as the favorite stock to gain +100% or more in the months ahead. They include
Stock #1: A Disruptive Force with Notable Growth and Resilience
Stock #2: Bullish Signs Signaling to Buy the Dip
Stock #3: One of the Most Compelling Investments in the Market
Stock #4: Leader In a Red-Hot Industry Poised for Growth
Stock #5: Modern Omni-Channel Platform Coiled to Spring
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. While not all picks can be winners, previous recommendations have soared +171%, +209% and +232%.
Download Atomic Opportunity: Nuclear Energy's Comeback free today.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Align Technology, Inc. (ALGN): Free Stock Analysis Report
Cardinal Health, Inc. (CAH): Free Stock Analysis Report
Cencora, Inc. (COR): Free Stock Analysis Report
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
19 minutes ago
- Globe and Mail
Wall Street Is Watching This One Metric in Nvidia's Q2 -- Can It Deliver?
Nvidia (NASDAQ: NVDA) recently became the world's first $4 trillion tech titan -- but the second quarter could be the spark for its next mega move. With quantum computing breakthroughs, artificial intelligence (AI) networking dominance, and a stealth China rebound on the horizon, this earnings report might deliver more than Wall Street expects. *Stock prices used were the market prices of July 28, 2025. The video was published on Aug. 2, 2025. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » Should you invest $1,000 in Nvidia right now? Before you buy stock in Nvidia, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Nvidia wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $624,823!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,064,820!* Now, it's worth noting Stock Advisor's total average return is 1,019% — a market-crushing outperformance compared to 178% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025 Rick Orford has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Nvidia. The Motley Fool has a disclosure policy. Rick Orford
Globe and Mail
an hour ago
- Globe and Mail
Stocks in play: Bausch + Lomb Corporation
Today announced its second-quarter 2025 financial results. Revenue of $1.278 Billion. GAAP Net Loss of $62 Million. Bausch + Lomb Corporation shares are trading down $0.43 at $19.74.
Globe and Mail
3 hours ago
- Globe and Mail
Is C3.ai Stock a Buy?
Key Points business has benefited from organizations rushing to adopt AI solutions, such as the U.S. Air Force. The company reached record revenue in its fiscal fourth quarter, and forecasts more sales growth ahead. is not profitable, and a change in CEO is on the horizon. 10 stocks we like better than › Artificial intelligence (AI) stocks have been hot, and many experienced strong growth in 2025 alone. For example, this year, AI luminaries Nvidia and Broadcom saw shares soar more than 30% and 26%, respectively, through July 28. But one lackluster AI stock has been (NYSE: AI). Its shares are down about 25% this year through July 28. Could the price drop signal an opportunity to scoop up shares at a discount? After all, the global AI market is forecast to expand from $244 billion in 2025 to $1 trillion by 2031, providing a tailwind for business. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » The reality is that evaluating whether to purchase its stock requires digging into the company. Let's delve into to help assess if it's a sound investment for the long run. A look at business is an enterprise AI applications business servicing the needs of corporate and government organizations. Its customers include the U.S. Department of Defense, Dow Inc., and ExxonMobil. The company built a network of partnerships to assist in selling its solutions, which includes Microsoft and energy giant Baker Hughes. These alliances resulted in partners closing 73% of the customer agreements signed in 2025 fiscal year, ended April 30. business model translated into record revenue of $108.7 million, a 26% year-over-year increase, in its fiscal fourth quarter. For the full year, sales grew 25% year over year to $389.1 million. The company's offerings have proven popular with customers. In May, the U.S. Air Force expanded its contract with from $100 million to $450 million to supply predictive analytics that proactively identify aircraft maintenance needs. In June, Univation Technologies, a Dow subsidiary, adopted predictive maintenance capabilities to deliver to its petrochemical industry customers. pros and cons The company's customer wins this year suggest more revenue expansion to come. In fact, forecasts fiscal 2026 sales to reach between $447.5 million and $484.5 million, another solid year of growth over fiscal 2025's $389.1 million. Despite rising sales, business isn't profitable. It ended fiscal 2025 with an operating loss of $324.4 million, deepening from a $318.3 million loss in the prior year. Costs increased from adding employees to support its business growth. On top of that, a health issue struck CEO Tom Siebel this year, and the company is now searching for a successor. This is unfortunate news, and it contributed to the decline in share price. The stock price drop is understandable, since a leadership change risks disrupting the company's future success. However, is striving to cut costs and strengthen its finances. Management expects to be free-cash-flow (FCF) positive by next year. It ended fiscal 2025 with negative FCF of $44.4 million, which is an improvement over the previous year's $90.4 million in negative FCF. Its balance sheet shows is well capitalized with total assets of $1 billion, $742.7 million of which represent cash, cash equivalents, and short-term investments. Total liabilities were $187.6 million. Deciding whether to buy stock Although isn't profitable, its strategy to prioritize business expansion over immediate profit follows a typical approach adopted by many companies in the technology sector. As long as year-over-year revenue growth remains strong and it continues to improve its financials, such as reaching positive FCF, operating loss isn't a major concern. The impending departure of its CEO is regrettable, but Siebel intends to continue shepherding the company as executive chairman. This positions for a smooth leadership transition. With plenty of positives in its favor, does this mean now is the time to buy shares? To answer that, here's a look at its stock's price-to-sales (P/S) ratio with a comparison to Microsoft's, given Microsoft sells offerings, and is a prominent AI business in its own right. Data by YCharts. The chart reveals valuation has significantly improved, as evidenced by the substantial drop in its P/S multiple from its late 2024 peak. This multiple is now considerably lower than Microsoft's, further highlighting attractive valuation. This, combined with growing sales, a robust balance sheet, and strengthening free cash flow, makes stock a compelling investment opportunity. Should you invest $1,000 in right now? Before you buy stock in consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $624,823!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,064,820!* Now, it's worth noting Stock Advisor's total average return is 1,019% — a market-crushing outperformance compared to 178% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. *Stock Advisor returns as of July 29, 2025
